Pathophysiology of diabetes mellitus type 2: Beyond the duo "insulin resistance-secretion deficit";Fisiopatología de la diabetes mellitus tipo 2: Más allá del dúo "resistencia insulina-déficit de secreción"

Nutricion Hospitalaria

Volumn 28, Issue SUPPL2, 2013, Pages 78-87

  Carrera Boada, C A ^a   Martinez Moreno J M ^b  

^a Hospital de Clinicas Caracas   (Venezuela)

^b UNIVERSITY OF MÁLAGA   (Spain)

Author keywords

Diabetes; Glucose; Insulin resistance

Indexed keywords

INSULIN;

ARTICLE; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; SECRETION (PROCESS);

DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN; INSULIN RESISTANCE;

EID: 84876441809     PISSN: 02121611     EISSN: 16995198     Source Type: Journal    
DOI: 10.3305/nh.2013.28.sup2.6568     Document Type: Article

References (98)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33 (Suppl. 1): S62-S69.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27 (5): 1047-1053.
3. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104 (6): 787-794.
4. Müller WA, Faloona GR, Aguilar-Parada E, Unger RH. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med 1970; 283 (3): 109-115.
5. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia 2004; 47: 31-39.
6. Mari A, Wahren J, DeFronzo RA, Ferrannini E. Glucose absorption and production following oral glucose: comparison of compartmental and arteriovenous-difference methods. Metabolism 1994; 43: 1419-1425.
7. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus: metabolic and molecular implications for identifying diabetes genes. Diabetes 1997; 5: 177-269.
8. Mitrakou A, Kelley D, Veneman T, Jensen T, Pangburn T, Reilly J et al. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. Diabetes 1990; 39: 1381-1390.
9. Cherrington AD. Control of glucose uptake and release by the liver in vivo. Diabetes 1999; 48: 1198-1214.
10. Mandarino L, Bonadonna R, McGuinness O, Wasserman D. Regulation of muscle glucose uptake in vivo. In: Jefferson LS, Cherrington AD, editors. Handbook of physiology. The endocrine system, vol. 2. The endocrine pancreas and regulation of metabolism. Oxford: Oxford University Press; 2001, pp. 803-848.
11. Grill V. A comparison of brain glucose metabolism in diabetes as measured by positron emission tomography or by arteriovenous techniques. Ann Med 1990; 22: 171-175.
12. Bergman RN. Non-esterified fatty acids and the liver: why is insulin secreted into the portal vein? Diabetologia 2000; 43: 946-952.
13. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonsits provide a rational therapeutic approach. J Clin Endocrinol Metab 2004; 89: 463-478.
14. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997; 46: 3-10.
15. Groop LC, Bonadonna RC, Del Prato S, Ratheiser K, Zych K, Ferrannini E, DeFronzo R.A. Glucose and free fatty acid metabolism in non-insulin dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. J Clin Invest 1989; 84: 205-215.
16. Baron AD, Schaeffer L, Shragg P, Kolterman OG. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 1987; 36: 274-283.
17. Comuzzie AG, Williams JT, Martin LJ, Blangero J. Searching for genes underlying normal variation in human adiposity. J Mol Med 2001; 79: 57-70.
18. Dvorak RV, DeNino WF, Ades PA, Poehlman ET. Phenotypic characteristics associated with insulin resistance in metabolically obese but normalweight young women. Diabetes 1999; 48: 2210-2214.
19. Colditz GA, Willett WC, Stampfer MJ et al. Weight as a risk factor for clinical diabetes in women. Am J Epidemiol 1990; 132: 501-513.
20. Njolstad I, Arnesen E, Lund-Larsen PG. Sex differences in risk factors for clinical diabetes mellitus in a general population: a 12-year follow-up of the Finnmark Study. Am J Epidemiol 1998; 147: 49-58.
21. Field AE, Coakley EH, Must A et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 2001; 161: 1581-1586.
22. Hu FB, Manson JE, Stampfer MJ et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001; 345: 790-797.
23. Ruderman NB, Schneider SH, Berchtold P. The "metabolically-obese", normal-weight individual. Am J Clin Nutr 1981; 34: 1617-1621.
24. St-Onge MP, Janssen I, Heymsfield SB. Metabolic syndrome in normalweight Americans: new definition of the metabolically obese, normal-weight individual. Diabetes Care 2004; 27: 2222-2228.
25. Grundy SM, Brewer Jr HB, Cleeman JI, Smith Jr SC, Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-438.
26. Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest 1997; 100: 1166-1173.
27. Karelis AD, Faraj M, Bastard JP, St-Pierre DH, Brochu M, Prud'homme D, Rabasa-Lhoret R. The metabolically healthy but obese individual presents a favorable inflammation profile. J Clin Endocrinol Metab 2005; 90: 4145-4150.
28. Kraemer FB, Shen WJ. "Hormone-sensitive lipase: control of intracellular tri-(di-)acylglycerol and cholesteryl ester hydroly -sis". J Lipid Res 2002; 43 (10): 1585-1594.
29. Pouliot M-C, Desprès J-P, Nadeau A, Moorjani S, Prud'Homme D, Lupien PJ, Tremblay A, Bouchard C. Visceral obesity in men. Associations with glucose tolerance, plasma insulin and lipoprotein levels. Diabetes 1992; 41: 826-834.
30. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000; 106: 473-481
31. Ross R, Leger L, Morris D, de Guise J, Guardo R. Quantification of adipose tissue by MRI: relationship with anthropometric variables. J Appl Physiol 1992; 72: 787-795.
32. Ross R, Shaw KD, Martel Y, de Guise J, Avruch L. Adipose tissue distribution measured by magnetic resonance imaging in obese women. Am J Clin Nutr 1993; 57: 470-475.
33. Campra JL, Reynolds TB. The hepatic circulation. In: Arias IM, Popper H, Schachter D, Shafritz DA, eds. The liver: biology and pathobiology. New York: Raven Press; 1982; 627-645.
34. Parker DR, Carlisle K, Cowan FJ, Corrall RJ, Read AE. Postprandial mesenteric blood flow in humans: relationship to endogenous gastrointestinal hormone secretion and energy content of food. Eur J Gastroenterol Hepatol 1995; 7: 435-440.
35. Abate N, Garg A, Peshock RM, Stray-Gundersen J, Grundy SM. Relationships of generalized and regional adiposity to insulin sensitivity in men. J Clin Invest 1995; 96: 88-98.
36. Goodpaster BH, Thaete FL, Simoneau J-A, Kelley DE. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 1997; 46: 1579-1585.
37. Boden G. Free fatty acids (FFA), a link between obesity and insulin resistance. Front Biosci 1998; 47: d169-d17.
38. Kashyap S, Belfort R, Castaldelli A, Pratipanawatr T, Berria R, Pratipanawatr W, Bajaj M, Mandarino L, DeFronzo R, Cusi K. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 2003; 52: 2461-2474.
39. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonsits provide a rational therapeutic approach. J Clin Endocrinol Metab 2004; 89: 463-478.
40. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 1995; 44: 863-870.
41. McGarry JD. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002; 51: 7-18.
42. Shimabukuro M, Zhou Y-T, Levi M, Unger RH. Fatty acid induced b cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci USA 1998; 95: 2498-2502.
43. Prentki M, Corkey BE. Are the beta cells signaling molecules malonyl-CoA and cytosolic long-chain acyl-CoA implicated in multiple tissue defects of obesity and NIDDM? Diabetes 1996; 45: 273-283.
44. Goodyear LJ, Kahn BB. Exercise, glucose transport, and insulin sensitivity. Annu Rev Med 1998; 49: 235-261.
45. Zauner A, Nimmerrichter P, Anderwald C, Bischof M, Schiefermeier M, Ratheiser K, Schneeweiss B, Zauner C. Severity of insulin resistance in critically ill medical patients. Metabolism 2007; 56: 1-5.
46. Westermark P, Wernstedt C, Wilander E, Sletten K. A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas. Biochem Biophys Res Commun 1986; 140: 827-831.
47. Westermark P, Wernstedt C, O'Brien TD, Hayden DW, Johnson KH. Islet amyloid in type 2 human diabetes mellitus and adult diabetic cats contains a novel putative polypeptide hormone. Am J Path 1987; 127: 414-417.
48. Janson J, Ashley RH, Harrison D, McIntyre S, Butler PC. The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 1999; 48: 491-498.
49. Dobson CM. Principles of protein folding, misfolding and aggregation. Semin Cell Develop Biol 2004; 15: 3-16.
50. Gerich JE. The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev 1998; 19: 491-503.
51. Xiang AH, Wang C, Peters RK, Trigo E, Kjos SL, Buchanan TA. Coordinate changes in plasma glucose and pancreatic betacell function in Latino women at high risk for type 2 diabetes. Diabetes 2006; 55: 1074-1079.
52. Sakuraba H, Mizukami H, Yagihashi N, Wada R, Hanyu C, Yagihashi S. Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients. Diabetologia 2002; 45: 85-96.
53. Marchetti P, Del Guerra S, Marselli L et al. Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab 2004; 89: 5535-5541.
54. Bergman RN. Toward physiological understanding of glucose tolerance Minimal-model approach. Lilly lecture. Diabetes 1989; 38: 1512-1527.
55. Quoix N, Cheng-Xue R, Guiot Y, Herrera PL, Henquin JC, Gilon P. The GluCre-ROSA26EYFP mouse: a new model for easy identification of living pancreatic alpha-cells. FEBS Letters 2007; 581: 4235-4240.
56. Barnes AJ, Bloom SR. Pancreatectomised man: A model for diabetes without glucagon. Lancet 1976; 1: 219-222.
57. Asplin CM, Paquette TL, Palmer JP. In vivo inhibition of glucagon secretion by paracrine beta cell activity in man. J Clin Invest 1981; 68: 314-318.
58. Cryer PE. Glucagon and hyperglycaemia in diabetes. Clin Sci (Lond) 2008; 114: 589-590.
59. Unger RH, Grundy S. Hyperglycemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. Diabetologia 1985; 28: 119-121.
60. Donath MY, Ehses JA, Maedler K, Schumann DM, Ellingsgaard H, Eppler E, Reinecke M. Mechanisms of β-cell death in type 2 diabetes. Diabetes 2005; 54 (Suppl. 2): S108-S113.
61. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA, Kaiser N, Halban PA, Donath MY. Glucose-induced cell production of IL-1 contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110: 851-860.
62. Donath M, Storling J, Berchtold LA, Billestrup N, Mandrup-Poulsen T. Cytokines and β-cell biology: from concept to clinical translation. Endocr Rev 2008; 29: 334-350.
63. Scheuner D, Kaufman RJ. The unfolded protein response: a pathway that links insulin demand with β-cell failure and diabetes. Endocr Rev 2008; 29: 317-333.
64. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC. β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52: 102-110.
65. Haataja L, Gurlo T, Huang CJ, Butler PC. Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocr Rev 2008; 29: 303-316.
66. Muoio DM, Newgard CB. Molecular and metabolic mechanisms of insulin resistance and β-cell failure in type 2 diabetes. Nature reviews. Molecular Cell Biology 2008; 9: 193.
67. Welsh N, Margulis B, Borg LA, Wiklund HJ, Saldeen J, Flodstrom M, Mello MA, Andersson A, Pipeleers DG, Hellerstrom C, Eizirik DL. Differences in the expression of heat-shock proteins and antioxidant enzymes between human and rodent pancreatic islets: implications for the pathogenesis of insulin-dependentdiabetes mellitus. Mol Med 1995; 1: 806-820.
68. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002; 143 (11): 4397-4408.
69. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3: 153-165.
70. Lee YC, Brubaker PL, Drucker DJ. Developmental and tissuespecific regulation of proglucagon gene expression. Endocrinology 1990; 127: 2217-2222.
71. Eissele R, Goke R, Willemer S, Harthus HP, Vermeer H, Arnold R, Goke B. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest 1992; 22: 283-291.
72. Anini Y, Hansotia T, Brubaker PL. Muscarinic receptors control postprandial release of glucagon-like peptide-1: in vivo and in vitro studies in rats. Endocrinology 2002; 143: 2420-2426.
73. Hansen L, Deacon CF, Orskov C, Holst JJ. Glucagon-like peptide-1-(7-36) amide is transformed to glucagon-like peptide-1-(9-36) amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999; 140: 5356-5363.
74. Holst JJ. Glucagon-like peptide-1: from extract to agent: the Claude Bernard Lecture, 2005. Diabetologia 2006; 49: 253-260.
75. Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995; 136: 3585-3596.
76. Rask E, Olsson T, Soderberg S, Johnson O, Seckl J, Holst JJ, Ahren B. Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care 2001; 24: 1640-1645.
77. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon-like peptide-1 (7-36) amide and glucosedependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol 1993; 138: 159-166.
78. Roberge JN, Brubaker PL. Regulation of intestinal proglucagonderived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. Endocrinology 1993; 133: 233-240.
79. Cordier-Bussat M, Bernard C, Levenez F, Klages N, Laser-Ritz B, Philippe J, Chayvialle JA, Cuber JC. Peptones stimulate both the secretion of the incretin hormone glucagon-like peptide 1 and the transcription of the proglucagon gene. Diabetes 1998; 47: 1038-1045.
80. Reimer RA, Darimont C, Gremlich S, Nicolas-Metral V, Ruegg UT, Mace K. A human cellular model for studying the regulation of glucagon-like peptide-1 secretion. Endocrinology 2001; 142: 4522-4528.
81. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, Holst JJ. Determinants of the impaired secretion of glucagon- like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86: 3717-3723.
82. Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E, Ciani S, Fanelli A, Messeri G, Rotella CM. Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with type 2 diabetes mellitus. Diabet Med 2000; 17: 713-719.
83. Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R, Marks V. Attenuated GLP-1 secretion in obesity: cause or consequence? Gut 1996; 38: 916-919.
84. Toft-Nielsen MB, Damholt MB, Madsbad S et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86: 3717-3723.
85. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91: 301-307.
86. Hansen L, Deacon CF, Ørskov C, Holst JJ. Glucagon-like peptide-1-(7-36) amide is transformed to glucagon-like peptide-1-(9-36) amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine Endocrinology 1999; 140: 5356-5536.
87. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides Regul Pept 1999; 85: 9-24.
88. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP Gastroenterology 2007; 132: 2131-2157.
89. Preitner F, Ibberson M, Franklin I et al. Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors. J Clin Invest 2004; 113: 635-645.
90. Yip RG, Wolfe MM. GIP biology and fat metabolism. Life Sci 2000; 66: 91-103.
91. Trumper A, Trumper K, Trusheim H, Arnold R, Göke B, Horsch D. Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling Mol Endocrinol 2001; 15: 1559-1570.
92. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Hahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-3167.
93. Færch K, Borch-Johnsen K, Holst JJ, Vaag A. Pathophysiology and aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it matter for prevention and treatment of type 2 diabetes? Diabetologia 2009; 52: 1714-1723.
94. Steppan CM, Bailey S, Bhat S et al. The hormone resistin links obesity to diabetes. Nature 2001; 409 (18): 307-312.
95. Ford ES, Williamson DF, Liu W. Weight change and diabetes incidence: findings from a cohort of US adults. Am J Epidem 1997; 146 (3): 214-222.
96. Liljenquist JE et al. J Clin Invest 1977; 39: 369-374.
97. Mentlein R. Dipeptidylpeptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999; 85: 9-24.
98. Nauck MA, Vardarli I, Deacon CF et al. Diabetologia 2011; 54: 10-18.